174 related articles for article (PubMed ID: 33899342)
1. Sequence-Selective Covalent CaaX-Box Receptors Prevent Farnesylation of Oncogenic Ras Proteins and Impact MAPK/PI3 K Signaling.
Franz M; Mörchen B; Degenhart C; Gülden D; Shkura O; Wolters D; Koch U; Klebl B; Stoll R; Helfrich I; Scherkenbeck J
ChemMedChem; 2021 Aug; 16(16):2504-2514. PubMed ID: 33899342
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic K-Ras4B Dimerization Enhances Downstream Mitogen-activated Protein Kinase Signaling.
Muratcioglu S; Aydin C; Odabasi E; Ozdemir ES; Firat-Karalar EN; Jang H; Tsai CJ; Nussinov R; Kavakli IH; Gursoy A; Keskin O
J Mol Biol; 2020 Feb; 432(4):1199-1215. PubMed ID: 31931009
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of farnesylated CAAX protein processing by the intramembrane protease Rce1.
Manolaridis I; Kulkarni K; Dodd RB; Ogasawara S; Zhang Z; Bineva G; Reilly NO; Hanrahan SJ; Thompson AJ; Cronin N; Iwata S; Barford D
Nature; 2013 Dec; 504(7479):301-5. PubMed ID: 24291792
[TBL] [Abstract][Full Text] [Related]
4. Cellular compartmentalization in insulin action: altered signaling by a lipid-modified IRS-1.
Kriauciunas KM; Myers MG; Kahn CR
Mol Cell Biol; 2000 Sep; 20(18):6849-59. PubMed ID: 10958681
[TBL] [Abstract][Full Text] [Related]
5. Activated Ras induces cytoplasmic vacuolation and non-apoptotic death in glioblastoma cells via novel effector pathways.
Kaul A; Overmeyer JH; Maltese WA
Cell Signal; 2007 May; 19(5):1034-43. PubMed ID: 17210246
[TBL] [Abstract][Full Text] [Related]
6. The RAS-Effector Interface: Isoform-Specific Differences in the Effector Binding Regions.
Nakhaeizadeh H; Amin E; Nakhaei-Rad S; Dvorsky R; Ahmadian MR
PLoS One; 2016; 11(12):e0167145. PubMed ID: 27936046
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site.
Mazhab-Jafari MT; Marshall CB; Smith MJ; Gasmi-Seabrook GM; Stathopulos PB; Inagaki F; Kay LE; Neel BG; Ikura M
Proc Natl Acad Sci U S A; 2015 May; 112(21):6625-30. PubMed ID: 25941399
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic K-Ras and basic fibroblast growth factor prevent Fas-mediated apoptosis in fibroblasts through activation of mitogen-activated protein kinase.
Kazama H; Yonehara S
J Cell Biol; 2000 Feb; 148(3):557-66. PubMed ID: 10662780
[TBL] [Abstract][Full Text] [Related]
9. Insight into the mechanism of allosteric activation of PI3Kα by oncoprotein K-Ras4B.
Li X; Dai J; Ni D; He X; Zhang H; Zhang J; Fu Q; Liu Y; Lu S
Int J Biol Macromol; 2020 Feb; 144():643-655. PubMed ID: 31816384
[TBL] [Abstract][Full Text] [Related]
10. Sequence-selective molecular recognition of the C-terminal CaaX-boxes of Rheb and related Ras-proteins by synthetic receptors.
Düppe PM; Tran Thi Phuong T; Autzen J; Schöpel M; Yip KT; Stoll R; Scherkenbeck J
ACS Chem Biol; 2014 Aug; 9(8):1755-63. PubMed ID: 24856002
[TBL] [Abstract][Full Text] [Related]
11. N-terminally myristoylated Ras proteins require palmitoylation or a polybasic domain for plasma membrane localization.
Cadwallader KA; Paterson H; Macdonald SG; Hancock JF
Mol Cell Biol; 1994 Jul; 14(7):4722-30. PubMed ID: 8007974
[TBL] [Abstract][Full Text] [Related]
12. High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors.
Fiordalisi JJ; Johnson RL; Weinbaum CA; Sakabe K; Chen Z; Casey PJ; Cox AD
J Biol Chem; 2003 Oct; 278(43):41718-27. PubMed ID: 12882980
[TBL] [Abstract][Full Text] [Related]
13. Phosphatidylinositol 3-kinase requirement in activation of the ras/C-raf-1/MEK/ERK and p70(s6k) signaling cascade by the insulinomimetic agent vanadyl sulfate.
Pandey SK; Théberge JF; Bernier M; Srivastava AK
Biochemistry; 1999 Nov; 38(44):14667-75. PubMed ID: 10545192
[TBL] [Abstract][Full Text] [Related]
14. K-Ras
Feng H; Zhang Y; Bos PH; Chambers JM; Dupont MM; Stockwell BR
Biochemistry; 2019 May; 58(21):2542-2554. PubMed ID: 31042025
[TBL] [Abstract][Full Text] [Related]
15. The Ras/phosphatidylinositol 3-kinase and Ras/ERK pathways function as independent survival modules each of which inhibits a distinct apoptotic signaling pathway in sympathetic neurons.
Xue L; Murray JH; Tolkovsky AM
J Biol Chem; 2000 Mar; 275(12):8817-24. PubMed ID: 10722727
[TBL] [Abstract][Full Text] [Related]
16. Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity.
Elad-Sfadia G; Haklai R; Balan E; Kloog Y
J Biol Chem; 2004 Aug; 279(33):34922-30. PubMed ID: 15205467
[TBL] [Abstract][Full Text] [Related]
17. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes.
Lerner EC; Qian Y; Blaskovich MA; Fossum RD; Vogt A; Sun J; Cox AD; Der CJ; Hamilton AD; Sebti SM
J Biol Chem; 1995 Nov; 270(45):26802-6. PubMed ID: 7592920
[TBL] [Abstract][Full Text] [Related]
18. Downstream effectors of oncogenic ras in multiple myeloma cells.
Hu L; Shi Y; Hsu JH; Gera J; Van Ness B; Lichtenstein A
Blood; 2003 Apr; 101(8):3126-35. PubMed ID: 12515720
[TBL] [Abstract][Full Text] [Related]
19. Farnesyl protein transferase inhibitors as potential cancer chemopreventives.
Kelloff GJ; Lubet RA; Fay JR; Steele VE; Boone CW; Crowell JA; Sigman CC
Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):267-82. PubMed ID: 9107432
[TBL] [Abstract][Full Text] [Related]
20. Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways.
Grana TM; Rusyn EV; Zhou H; Sartor CI; Cox AD
Cancer Res; 2002 Jul; 62(14):4142-50. PubMed ID: 12124353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
